CA-USERTESTING
2.9.2020 10:02:12 CEST | Business Wire | Press release
UserTesting , a leading provider of on-demand human insights , has today announced a 400 percent customer growth in EMEA since opening its European headquarters in Edinburgh last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005297/en/
The huge growth has been as a direct result of changing consumer needs, perspectives, and behaviours caused by COVID-19, with brands and companies realising they must quickly relearn their customers, and do it remotely.
During the past year, UserTesting has gained over 100 new customers, including Brewin Dolphin, Depop, Post Office, Trussle, and HelloFresh–the leading meal-kit provider headquartered in Berlin. They join other well known European brands such as ASOS, Deliveroo, and Skyscanner, all of which are now embarking on their customer empathy journey with UserTesting.
Rapid customer insights
“UserTesting has cut our testing time in half, which has enabled us to scale testing and grow our UX Research team,” said James Villacci, Associate Director of UX Research at HelloFresh. “The level of support we've received has been tremendous, to the point that we see UserTesting more as a research partner. Prior to UserTesting, we were limited in how we could gather customer feedback, but now we can gain customer insights rapidly on a global level.”
To support its growing customer base across Europe, UserTesting has been building out its European talent, with an 8x growth in headcount–growing from 9 to 79 in just one year’s time and now with offices in Edinburgh, London, Berlin, and Oslo. This includes the recent acquisition of Teston , a European provider of multilingual experience testing for fast customer feedback in English, Norwegian, Swedish, German, French, and Danish.
Scottish CSR initiatives
UserTesting is also investing in Scotland’s tech community through two recent initiatives. UserTesting is supporting the charity Scotland Women in Technology (SWiT) via Hearts Women , and is also donating access to its platform to help enable the Scottish Tech Army to get fast feedback and insights on their technology projects, which are helping Scottish businesses that have been badly affected by COVID-19.
“We have one Scottish Tech Army team working on the public launch of a COVID-19 dashboard, and another team creating a product to allow our PPE Inventory Management service to be deployed to multiple charities and other organisations who are facing this logistical challenge,” said Andrew Rendle, Volunteer Project Manager, Scottish Tech Army.
Rendle added: “Without access to the UserTestingⓇ Platform, we would be relying on conventional wisdom and traditional testing approaches to design the interface, but thanks to UserTesting, we’ve been able to get in front of our intended audiences to collect the needed feedback to design the best user experience.”
About UserTesting
UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform , companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting has more than 1,500 subscription customers, including more than half of the world’s top brands, and has delivered human insights to over 35,000 companies to-date. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
